Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPAL study of apitegromab in infants with spinal muscular atrophy
2024-520130-29-00Phase 2Authorised
- Sponsor
- Scholar Rock
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, double-blind trial of apitegromab in spinal muscular atrophy (SMA) (2 arms), sponsored by Scholar Rock. Planned start Dec 2025; status: authorised.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2024-520130-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520130-29-00.